Matritech, Hybritech Inc. deal

NMPS reacquired Hybritech's co-marketing rights to NMPS's NMP-based bladder cancer products in the U.S. and Europe. NMPS (Cambridge, Mass.) had received $500,000 of the $800,000 available in R&D milestones. Hybritech acquired rights to the product, a nuclear matrix protein-based immunodiagnostic, under a 1990 agreement. NMPS CEO Stephen Chubb said Hybritech was a player in the oncology and urology market when the agreement was struck, "but they are no longer a dominant force." NMPS is in discussions with other companies that focus on oncology and urology. ...